| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 08/08/2001 | CN1306857A Medicine for strengthening physique and strengthening immunity |
| 08/08/2001 | CN1306834A Health product of cactus and its processing method |
| 08/08/2001 | CN1306831A Medicine for diabetic to restore sexual function |
| 08/08/2001 | CN1306830A Medicine for treating Type-11 diabetes |
| 08/08/2001 | CN1306752A Formulation and production process of Baile biscuit with dietary fiber having hypoglycemic function |
| 08/08/2001 | CN1069318C Cyclic gmp-specific phosphodiesterase inhibitors |
| 08/08/2001 | CN1069312C Substituted imidogen sulfamide, its preparation, use and medicines containing the same |
| 08/08/2001 | CN1069309C N-(aminopropyl)-N-phenyl-5,6,7,8-tetrahydronaphtalene-2-carboxamide derivative, preparation and application thereof |
| 08/08/2001 | CN1069203C Drug for curing diabetes and its prep. |
| 08/07/2001 | USRE37314 Pyrimidine derivatives |
| 08/07/2001 | US6271374 Stable crystalline (6S)- and (6R)-tetrahydrofolic acid |
| 08/07/2001 | US6271353 Antibodies specific for human adseverin |
| 08/07/2001 | US6271278 Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
| 08/07/2001 | US6271248 Substituted biphenysulfonamide endothelin antagonists |
| 08/07/2001 | US6271247 Binding to neuropeptide receptors |
| 08/07/2001 | US6271243 Pharmaceutical composition |
| 08/07/2001 | US6271030 For modulation of c/ebp beta (transcription factor enhancer-binding gene) expression and for treatment of diseases associated with expression of c/ebp beta |
| 08/07/2001 | US6270774 To increase levels of high density lipoprotein (hdl) and calcium ions, and decrease levels of free radicals and glucose in human blood plasma. |
| 08/07/2001 | US6270759 Method of using IL-11 for treating gingivitis |
| 08/07/2001 | CA2191101C Materials and methods for treatment of plaquing diseases |
| 08/07/2001 | CA2045883C Process for the extrusion preparation of actives granules |
| 08/02/2001 | WO2001055692A2 Neurosteroids as markers for alzheimer's disease |
| 08/02/2001 | WO2001055392A2 Nuclear hormone receptors |
| 08/02/2001 | WO2001055356A2 Human protein kinases and protein kinase-like enzymes |
| 08/02/2001 | WO2001055336A2 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055221A1 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 08/02/2001 | WO2001055219A2 scsCNTFR/NNT-1 FUSION PROTEIN |
| 08/02/2001 | WO2001055215A1 Therapeutic peptides |
| 08/02/2001 | WO2001055198A2 Dermo- and gastro-specific sphingolipid activator |
| 08/02/2001 | WO2001055172A2 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN |
| 08/02/2001 | WO2001055150A1 4-heteroaryl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof |
| 08/02/2001 | WO2001055149A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid |
| 08/02/2001 | WO2001055134A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 08/02/2001 | WO2001055132A1 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists |
| 08/02/2001 | WO2001055130A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 08/02/2001 | WO2001055122A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 08/02/2001 | WO2001055121A1 Azepine derivatives |
| 08/02/2001 | WO2001055115A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | WO2001055114A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 08/02/2001 | WO2001055112A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055105A1 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| 08/02/2001 | WO2001055098A1 Palatable arginine compounds and uses thereof for cardiovascular health |
| 08/02/2001 | WO2001055086A1 Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| 08/02/2001 | WO2001055085A1 Propionic acid derivatives and their use in the treatment of diabetes and obesity |
| 08/02/2001 | WO2001055078A1 Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| 08/02/2001 | WO2001054742A1 A medicinal aerosol formulation |
| 08/02/2001 | WO2001054741A1 A medicinal aerosol formulation |
| 08/02/2001 | WO2001054731A2 Ligand conjugates and methods for preparing same |
| 08/02/2001 | WO2001054730A1 METHOD FOR PRODUCING A COENZYME Q10 / η-CYCLODEXTRIN COMPLEX |
| 08/02/2001 | WO2001054728A1 NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
| 08/02/2001 | WO2001054725A1 Remedies and preventives for dental diseases |
| 08/02/2001 | WO2001054721A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases |
| 08/02/2001 | WO2001054711A2 Use of neurotoxins for treating diabetes |
| 08/02/2001 | WO2001054700A1 Pharmaceutical preparation and method for treatment of diabetes |
| 08/02/2001 | WO2001054699A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | WO2001054694A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | WO2001054686A2 L-arginine in combination with other compounds for treating cardiovascular diseases |
| 08/02/2001 | WO2001054681A2 Composition for treatment of stress |
| 08/02/2001 | WO2001054669A1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor |
| 08/02/2001 | WO2001054668A1 Pharmaceutical compositions comprising a hmg reductase inhibitor |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001054664A1 A method of administering a medicinal aerosol formulation |
| 08/02/2001 | WO2001054659A2 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (pnp) |
| 08/02/2001 | WO2001016114A3 Heterocyclic compounds and methods for modulating cxcr3 function |
| 08/02/2001 | WO2001014548A3 New g-protein coupled receptor and dna sequences thereof |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2001001969A3 Methods of treating and/or suppressing weight gain |
| 08/02/2001 | WO2000050580A3 Composition, methods and reagents for the synthesis of a soluble form of human phex |
| 08/02/2001 | WO2000047625A3 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 08/02/2001 | WO1999066918A8 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 08/02/2001 | US20010011124 Genetic engineering |
| 08/02/2001 | US20010011096 Antidiabetic agent; dietetics |
| 08/02/2001 | US20010011082 Mixture with chelate compound; bone disorders |
| 08/02/2001 | US20010011081 Pharmaceutical composition comprising L- carnitine or alkanoyl L-carnitine for the prevention and treatment of diseases brought about by lipid metabolism disorders |
| 08/02/2001 | US20010011072 Skin disorders; kidney and liver disorders |
| 08/02/2001 | US20010011070 Reduce concentration of phenylalanine in blood |
| 08/02/2001 | US20010010934 Polypeptides that regulate epithelial specific gene expression; hypoproliferative disorders; medical diagnosis |
| 08/02/2001 | US20010010929 Polynucleotides and polypeptides belonging to the uncoupling proteins family |
| 08/02/2001 | US20010010928 Protozoan expression system |
| 08/02/2001 | US20010010921 Cell-free and cell-based assays for screening drugs to treat eating disorders; dietetics; obesity, cachexia |
| 08/02/2001 | US20010010825 Rapidly disintegrable solid preparation |
| 08/02/2001 | US20010010820 Delaying onset of insulin dependent diabetes mellitus by administering immunologically active monoclonal antibody against glutamic acid decarboxylase coupled to a nonimmunogenic polymer that provides shell around antibody |
| 08/02/2001 | DE10038108A1 Pharmazeutische Zusammensetzungen Pharmaceutical compositions |
| 08/02/2001 | CA2786722A1 Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors |
| 08/02/2001 | CA2401086A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases |
| 08/02/2001 | CA2398821A1 Composition for treatment of stress |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398631A1 Slimming cosmetic composition comprising as an ative agent a plant extract containing a plant natriuretic peptide (pnp) |
| 08/02/2001 | CA2398564A1 Nuclear hormone receptors |
| 08/02/2001 | CA2398561A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398435A1 Novel ligands and methods for preparing same |
| 08/02/2001 | CA2398430A1 Human protein kinases and protein kinase-like enzymes |
| 08/02/2001 | CA2398358A1 The neurosteroid dhea as a marker for neuropathologies |
| 08/02/2001 | CA2398206A1 Pharmaceutical preparation and method for treatment of diabetes |
| 08/02/2001 | CA2398199A1 Novel therapeutic agents that use a .beta.3 agonist |
| 08/02/2001 | CA2397493A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | CA2397267A1 Peptide fragments and uses thereof as type-1 interferon antagonist |
| 08/02/2001 | CA2396781A1 A method of administering a medicinal aerosol formulation |